Abstract
Background Early detection of cancer is crucial for reducing the global burden of cancer and saving lives, but effective screening tests for many cancers do not exist. Genomics-based liquid biopsy tests for screening multiple cancers at once have been developed, but they have low sensitivity for early-stage cancers and are expensive. Recent advancements in measuring protein abundances in plasma offer new opportunities for developing multi-cancer screening tests.
Methods We collected plasma samples from 440 individuals, healthy and diagnosed with 18 various types of early-stage solid tumours. Using Proximity Extension Assay, we measured more than 3000 high and low-abundance proteins in each sample. Then, using a multi-step statistical approach, we identified a limited set of proteins that could detect early-stage cancers and their tissue of origin with high diagnostic accuracy.
Findings Our sex-specific cancer detection consisting of 10 proteins showed high accuracy for both males (AUC: 0.98) and females ((AUC: 0.983). At stage I and at the specificity of 99%, our detection panels were able to identify 89% of cancers among males and 75% of cancers among females.
Our sex-specific localization panels consisted of 150 proteins and were able to identify the tissue of origin of most cancers in more than 80% of cases. The analysis of the plasma concentrations of proteins selected showed that almost all the proteins were in the low-concentration part of the human plasma proteome.
Interpretation The proteome-based screening test showed promising performance compared with other technologies and could be a starting point for developing a new generation of screening tests for the early detection of cancer and potentially other chronic diseases. This new approach may provide a more accessible and cost-effective alternative to existing methods for cancer detection and may help reduce cancer mortality rates globally.
Competing Interest Statement
The authors hold shares and/or employed by Novelna Inc.
Funding Statement
This study was funded by Novelna Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Ukraine Association of Biobank (UAB) waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
